Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

N/A
2(50.0%)
Early Phase 1
1(25.0%)
Phase 1
1(25.0%)
4Total
N/A(2)
Early Phase 1(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04621435Phase 1Recruiting

Imaging of Solid Tumors Using FAP-2286

Role: collaborator

NCT06630845Not ApplicableRecruiting

Comparison of Whole Body DWI to FDG PET

Role: collaborator

NCT02287701Not ApplicableCompleted

Exploratory Investigation of Advanced PET/MRI Metrics for Bladder Cancer Characterization

Role: collaborator

NCT01673802Early Phase 1Completed

The Role of Gadoxetate (Eovist) Enhanced CT in Evaluating Cholangiocarcinoma

Role: collaborator

All 4 trials loaded